Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ENTA
- Price
- 12.80
- Stock movement up
- +0.23 (1.83%)
- Company name
- Enanta Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 369.44M
- Ent value
- 553.16M
- Price/Sales
- 5.66
- Price/Book
- 5.71
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 16.17%
- 1 year return (CAGR)
- 150.00%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ENTA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.66 |
| Price to Book | 5.71 |
| EV to Sales | 8.47 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 28.86M |
| EPS (TTM) | -3.83 |
| FCF per share (TTM) | -1.50 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 65.32M |
| Gross profit (TTM) | 65.32M |
| Operating income (TTM) | -85.35M |
| Net income (TTM) | -81.89M |
| EPS (TTM) | -3.83 |
| EPS (1y forward) | -2.50 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -130.65% |
| Profit margin (TTM) | -125.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 32.30M |
| Net receivables | 6.88M |
| Total current assets | 204.34M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 96.75M |
| Total assets | 280.73M |
| Accounts payable | 1.95M |
| Short/Current long term debt | 201.06M |
| Total current liabilities | 48.55M |
| Total liabilities | 216.01M |
| Shareholder's equity | 64.72M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -19.27M |
| Capital expenditures (TTM) | 12.90M |
| Free cash flow (TTM) | -32.17M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -126.53% |
| Return on Assets | -29.17% |
| Return on Invested Capital | -83.07% |
| Cash Return on Invested Capital | -32.63% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.53 |
| Daily high | 13.00 |
| Daily low | 12.53 |
| Daily Volume | 260K |
| All-time high | 126.37 |
| 1y analyst estimate | 19.13 |
| Beta | 0.97 |
| EPS (TTM) | -3.83 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 9 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ENTA | S&P500 | |
| Current price drop from All-time high | -89.87% | -0.89% |
| Highest price drop | -96.63% | -19.00% |
| Date of highest drop | 10 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -93.12% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
369.44M
Marketcap category
Small-cap
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Employees
120
Website
Investor relations
-
SEC filings
CEO
Jay R. Luly
Country
USA
City
Watertown
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page